Ayurvedic manangement of Adolescent Nonalcoholic fatty liver disease

ADD-ON EFFECTIVENESS OF BHÅªNIMBÄ?DI GHANA CAPSULE ALONG WITH DIET AND LIFESTYLE MODIFICATION AMONG ADOLESCENT NAFLD - A RANDOMIZED CONTROLLED CLINICAL TRIAL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/04/051376

Enrollment

Registered

2023-04-06

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patient with liver stiffness 7.1 to 9.9 kPa in FibroScan.

Exclusion criteria

Exclusion criteria: Patients with 1.documented cause of chronic liver disease other than NASH 2.suffering from anemia and other diseases that could increase ALT levels such as Hepatitis, Positive HBsAg, positive anti-human immunodeficiency virus, positive hepatitis C virus-RNA. 3.History of drugs known to induce steatosis (systemic glucocorticoids, tetracycline, anabolic steroids, salicylates, tamoxifen, valproate, amiodarone, or prednisone). 4.History of drugs known to induce affect body weight (Treatment with phentermine, lorcaserin orlistat, zonisamide, topiramate, bupropion, or naltrexone). 5.Autoimmune liver disease, metabolic liver disease, Wilson disease.

Design outcomes

Primary

Measure	Time frame
Reduction in score of Liver stiffness in FibroScanTimepoint: Before treatment 0 day and after treatment 90th day.	—

Secondary

Measure	Time frame
Reduction of Paediatric NAFLD fibrosis score.Timepoint: 0 day - 90th day	—

Countries

India

Contacts

Public ContactDr Aparna Dileep

All India Institute of Ayurveda, New Delhi

ayuarun@gmail.com8506821947

Outcome results